Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | CKS1B | P61024 | 1/20 | 0.37 |
| ▸ | SKP1 | P63208 | 1/20 | 0.37 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5355169 | 0.84 | TLR7 (0.52) | TLR7 | |
| SCHEMBL5351277 | 0.83 | BCHE (0.38) | BCHEMEN1NPC1GAARAB9A | |
| SCHEMBL1233136 | 0.83 | TLR7 (0.43) | BCHEMEN1NPC1GAARAB9A | |
| SCHEMBL5362245 | 0.81 | TLR7 (0.43) | BCHEMEN1GAAKMT2ATLR7 | |
| SCHEMBL12888420 | 0.81 | TLR7 (0.48) | BCHETLR7 | |
| SCHEMBL6106028 | 0.80 | MAPT (0.37) | MEN1RAB9AKMT2ATLR7BRD4 | |
| SCHEMBL6494409 | 0.80 | TLR7 (0.54) | GAATLR7 | |
| SCHEMBL5350844 | 0.80 | TLR7 (0.52) | BCHETLR7 | |
| SCHEMBL5344983 | 0.79 | DYRK1A (0.47) | BCHEDRD2TLR7BRD4DYRK1A | |
| SCHEMBL1232968 | 0.78 | TLR7 (0.45) | BCHEDRD2TLR7BRD4DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157453-B2 | Urea substituted imidazoquinolines | 3M INNOVATION PROPERTIES COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20050131009-A1 | Urea substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-06-16 | — | — | US | disclosed |
| US-6897221-B2 | Urea substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-05-24 | — | — | US | disclosed |
| US-6784188-B2 | ADMINISTERING TO A MAMMAL 1H-IMIDAZO(4,5-C)QUINOLINE RING CONTAINING COMPOUND FOR THE TREATMENT OF DISEASES, INCLUDING VIRAL AND NEOPLSATIC DISEASES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-08-31 | — | — | US | disclosed |
| US-20040167154-A1 | Urea substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-08-26 | — | — | US | disclosed |
| US-20040019048-A1 | Urea substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167154-A1 | Urea substituted imidazoquinolines | IFNG, EIF2AK2, IRF3 | BCHE 3289/4885MEN1 3889/4885NPC1 2245/4885 |
| US-20040019048-A1 | Urea substituted imidazoquinolines | IFNG, EIF2AK2, IRF3 | BCHE 3289/4885MEN1 3889/4885NPC1 2245/4885 |
| US-20050131009-A1 | Urea substituted imidazoquinolines | IFNG, EIF2AK2, IRF3 | BCHE 3289/4885MEN1 3889/4885NPC1 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.